Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT05510063 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

371

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Humira (Adalimumab)
DRUG: SB5 (Adalimumab Biosimilar)

Sponsor

Samsung Bioepis Co., Ltd.

Collaborators

[object Object]